Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21972245 | 0.90 | LMNA (0.53) | LMNADRD2DRD3CA12CA1 | |
| SCHEMBL21971000 | 0.85 | LMNA (0.49) | LMNADRD2DRD3CA12CA1 | |
| SCHEMBL21971395 | 0.84 | LMNA (0.54) | LMNADRD2DRD3CA12CA1 | |
| SCHEMBL21971404 | 0.84 | LMNA (0.58) | LMNADRD2DRD3CA12CA1 | |
| SCHEMBL12978570 | 0.81 | LMNA (0.69) | LMNADRD2DRD3CA12CA1 | |
| SCHEMBL29414076 | 0.81 | LMNA (0.69) | LMNADRD2DRD3CA12CA1 | |
| SCHEMBL20739825 | 0.80 | LMNA (0.54) | LMNADRD2DRD3KDM4EMAPT | |
| SCHEMBL21970635 | 0.77 | HIF1A (0.47) | LMNADRD2DRD3CA12CA1 | |
| SCHEMBL21970999 | 0.75 | LMNA (0.56) | LMNADRD2DRD3KDM4EMAPT | |
| SCHEMBL20637698 | 0.74 | KDM4E (0.47) | LMNAKDM4EMGLLMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109336852-B | Non-fullerene electron transport material and synthetic method and application thereof | 江苏大学 | 2022-03-22 | — | — | CN | claimed |
| CN-109336852-A | A kind of non-fullerene electron transport material and its preparation method and use | 江苏大学 | 2019-02-15 | — | — | CN | claimed |
| CN-109336852-B | Non-fullerene electron transport material and synthetic method and application thereof | 江苏大学 | 2022-03-22 | — | — | CN | disclosed |
| US-11046655-B2 | Compound and method for producing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20200140394-A1 | NOVEL COMPOUND AND METHOD FOR PRODUCING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-07 | — | — | US | disclosed |
| CN-109336852-A | A kind of non-fullerene electron transport material and its preparation method and use | 江苏大学 | 2019-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140394-A1 | NOVEL COMPOUND AND METHOD FOR PRODUCING SAME | CBR3, NR2E3, NR5A2 | LMNA 4733/4885DRD2 341/4885DRD3 88/4885 |
| US-11046655-B2 | Compound and method for producing same | CBR3, NR5A1, NR2E3 | LMNA 4570/4885DRD2 260/4885DRD3 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.